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Facioscapulohumeral muscular dystrophy (FSHD), the most prevalent myopathy 
afflicting both children and adults, is strongly associated with epigenetic changes of the 
4q35-localized macrosatellite D4Z4 repeat. Recent studies propose that FSHD 
pathology is caused by the misexpression and missplicing of the DUX4 (double 
homeobox 4) gene, encoded within the repeat array, resulting in production of a 
pathogenic protein, DUX4-FL.  We have analyzed DUX4 mRNA and protein expression 
in a large collection of myogenic cells and muscle biopsies derived from muscles of 
FSHD1 affected subjects and their unaffected first-degree relatives.  We confirmed that 
stable DUX4-fl mRNA and protein were expressed in myogenic cells and muscle tissues 
derived from FSHD affected subjects, including several genetically diagnosed adults yet 
to show clinical manifestations of the disease; however, there was great individual and 
familial variation in the levels of DUX4-FL.  In addition, we found DUX4-fl mRNA and 
protein expression in muscle biopsies and myogenic cells from genetically unaffected 
relatives of the FSHD subjects, although at a significantly lower frequency.  These 
results establish that DUX4-fl expression per se is not sufficient for FSHD muscle 
pathology.  To investigate if subtle differences in the epigenetic status of the 4q35 region 
could account for the wide variation in DUX4-fl expression among FSHD1 subjects and 
potentially the spurious expression in certain unaffected controls, family cohorts of 
myogenic cells from FSHD1 subjects were tested for their sensitivity to small molecules 
that can alter the chromatin state.  We find that myogenic cells from FSHD1 subjects are 
overall epigenetically poised to express DUX4 compared with unaffected subjects; 
however, FSHD1 subjects show individual differences in their capacity to express DUX4-
fl in response to DNA demethylation and blocking histone deacetylation.  Therefor, 
individual differences in the epigenetic status likely impacts progression of disease 
pathology, variability in age of onset, disease severity, and asymmetry of affected 
muscles.   
 
 
